Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group C05 (Vasoprotectives)

02 October 2009

At the Danish Medicines Agency’s request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC group C05 (Vasoprotectives).

The Reimbursement Committee’s recommendation can be read in the factbox to the right (in Danish only). The recommendation contains a list of links to the references which the Reimbursement Committee has emphasised in its recommendation.

On 1 October 2009, the Danish Medicines Agency launched a consultation of the companies whose medicinal products are comprised by the Committee’s recommendation. A copy of the Danish Medicines Agency’s letter can be seen in the factbox to the right (in Danish only).

The consultation is open until 30 October 2009.

Moreover, we have sent a notification about the Reimbursement Committee’s recommendation to the Danish Endocrine Society, Danish Society of Cardiology, Danish Society for Vascular Surgery, Danish Medical Society, Danish Neurological Society, Danish Orthopaedic Society, Danish Society of Radiology, Danish College of General Practitioners, Danish Society of Clinical Pharmacology, Danish Society of Clinical Physiology and Nuclear Medicine, Danish Wound Healing Society and Danish Society on Thrombosis and Haemostasis. In addition, the National Board of Health and the Institute for Rational Pharmacotherapy have been briefed.

For further information, please contact the Reimbursement Department at medicintilskud@dkma.dk.

Danish Medicines Agency, 2 October 2009

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.


...